Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Protocol
  • Published:

Preparation of integrin α(v)β(3)-targeting Ab 38C2 constructs

Abstract

This protocol describes the preparation of Ab constructs using agents that target cells expressing integrins αvβ3 and αvβ5, and the monoclonal aldolase Ab 38C2. The targeting agents are equipped with a diketone or vinylketone linker, and selectively react through the reactive Lys residues in the Ab binding sites to form 38C2 conjugates or chemically programmed 38C2 (i.e., cp38C2). The targeting agent possessing a diketone linker reacts with the Lys residues forming an enaminone derivative. By contrast, the vinylketone linker is used as the corresponding acetone adduct (i.e., a pro-vinylketone linker), and this pro-adapter undergoes a 38C2-catalyzed retro-aldol reaction to produce the vinylketone linker, which forms a Michael-type adduct with the Lys residues. The Ab construct formation is achieved in <1 h for the diketone compounds at ambient temperature, and in 2–16 h using the pro-vinylketone linker at 37 °C. The 38C2 constructs are retargeted to cells over-expressing integrins, and are potential candidates for immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Regioselective modification of Ab 38C2.
Figure 2: Synthesis of 38C2 constructs (cp38C2).
Figure 3: Syntheses of the αvβ3- and αvβ5-integrin-targeting RGD mimetics, 1 and 2, equipped with a diketone or provinylketone function.
Figure 4: Catalytic activity of 38C2 constructs, 38C2-1 (prepared from compound 1) and 38C2-2 (prepared from compound 2) compared with unmodified 38C2 and buffer alone.
Figure 5: Mass spectral analysis of cp38C2.
Figure 6: Synthesis of the precursors of compounds 1 and 2.

Similar content being viewed by others

References

  1. Hale, G. Therapeutic antibodies: Delivering the promise? Adv. Drug Delivery Rev. 58, 633–639 (2006).

    Article  CAS  Google Scholar 

  2. Kohzoh, I. & Akinori, T. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714–727 (2006).

    Article  Google Scholar 

  3. Rader, C., Sinha, S.C., Popkov, M., Lerner, R.A. & Barbas, C.F., III A chemically programmed monoclonal antibody for cancer therapy. Adapter immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci. USA 100, 5396–5400 (2003).

    Article  CAS  Google Scholar 

  4. Guo, F. et al. Breaking the one antibody one target axiom. Proc. Natl. Acad. Sci. USA 103, 11009–11014 (2006).

    Article  CAS  Google Scholar 

  5. Popkov, M., Rader, C., Gonzalez, B., Sinha, S.C. & Barbas, C.F., III Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int. J. Cancer 119, 1194–1207 (2006).

    Article  CAS  Google Scholar 

  6. Doppalaudi, V.R. et. al. Chemically programmed antibodies: Endothelin receptor targeting Cov X-Bodies. Biorg. Med. Chem. Lett. 17, 501–506 (2006).

    Article  Google Scholar 

  7. Li, L.-S. et. al. Chemical-adaptor immunotherapy: design, synthesis and evaluation of novel integrin-targeting devices. J. Med. Chem. 47, 5630–5640 (2004).

    Article  CAS  Google Scholar 

  8. Wagner, J., Lerner, R.A. & Barbas, C.F., III Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 270, 1797–1800 (1995).

    Article  CAS  Google Scholar 

  9. Rader, C. et al. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J. Mol. Biol. 332, 889–899 (2003).

    Article  CAS  Google Scholar 

  10. Kok, R.J. et al. Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjugate Chem. 13, 128–135 (2002).

    Article  CAS  Google Scholar 

  11. Lu, Y. et al. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Mol. Cancer Ther. 5, 3258–3267 (2006).

    Article  CAS  Google Scholar 

  12. Duggan, M.E. et al. Nonpeptide αvβ3 antagonists. 1. Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist. J. Med. Chem. 43, 3736–3745 (2000).

    Article  CAS  Google Scholar 

  13. List, B., Barbas, C.F., III & Lerner, R.A. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis. Proc. Natl. Acad. Sci. USA 95, 15351–15355 (1998).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the Skaggs Institute for Chemical Biology and National Institutes of Health (grant number: RO1 CA120289 to S.C.S. and RO1CA104045 to C.F.B.) for financial support, C. Rader of the National Cancer Institute for helpful discussions and D. Kubitz for supplying Ab 38C2.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Subhash C Sinha.

Ethics declarations

Competing interests

Patents related to this work have been licensed to CovX, Inc. in which C.F.B., R.A.L., and S.C.S. maintain an equity position.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sinha, S., Das, S., Li, LS. et al. Preparation of integrin α(v)β(3)-targeting Ab 38C2 constructs. Nat Protoc 2, 449–456 (2007). https://doi.org/10.1038/nprot.2007.3

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nprot.2007.3

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing